Popular Articles

Poniard Pharmaceuticals Announces Positive Efficacy And Safety Data From Phase 2 Clinical Trial Of Picoplatin In Men With Metastatic Prostate Cancer
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its Phase 2 clinical trial of picoplatin in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The data demonstrate that picoplatin in combination with docetaxel and prednisone is active as first-line therapy for metastatic CRPC. This was demonstrated by several endpoints, including reductions in prostate specific antigen (PSA) levels, disease control as measured by tumor response, and progression-free survival (PFS). Results also continue to show that picoplatin can be safely administered every three weeks for up to 10 cycles concurrently with full doses of docetaxel and prednisone, the standard treatment for CRPC. In addition, no neurotoxicity was observed in these patients.
generic viagra online
Senate Democrats Meet With White House Adviser To Craft Response To Republican Criticism On Health Reform
Senate Democrats on Wednesday worked with senior White House adviser David Axelrod to craft a health care message focused on affordability and choice, the AP/Contra Costa Times reports (Werner, AP/Contra Costa Times, 5/13). The meeting followed the release of a memo last week by Republican strategist Frank Luntz outlining how to criticize Democratic plans for health reform (Budoff Brown/McGrane, Politico, 5/13). Senate Majority Whip Richard Durbin (D-Ill.) said Luntz"s memo was "an interesting catalyst for us" (AP/Contra Costa Times, 5/13).Axelrod presented Democrats with polling data about what U.S. residents are seeking from a health care overhaul and discussed better word choices, such as "shared responsibility" rather than "mandates" for coverage requirements. According to CongressDaily, the meeting centered Democrats on a coordinated message that the U.S. health care system must be affordable and accessible and should be patient-focused (Edney/Condon, CongressDaily, 5/13). Sen. Evan Bayh (D-Ind.) said that many Democrats felt "unease that we did not have a strategy" to answer the attacks coming from Republicans (Pear, New York Times, 5/14). Senate Finance Committee Chair Max Baucus (D-Mont.) said, "Everybody in the room had been a little nervous that, "Gee, Democrats don"t have their act together"" (CongressDaily, 5/13). However, Bayh said that "Axelrod came to reassure us that they do have a strategy" (New York Times, 5/14). Durbin said, "This is an effort to coordinate our message so we present a health care reform effort the American people trust" (Armstrong, CQ Today, 5/13). According to Durbin, Axelrod emphasized that Democrats should continue with the campaign theme that the goal of an overhaul is to "fix what"s broken in the system and preserve what"s good" (Young, The Hill, 5/13).Sen. Charles Schumer (D-N.Y.) said, "We believe the public shares our views. But we don"t want to be overwhelmed by either res, messaging or boots on the ground." He added, "We won"t make the mistake of 1993-94." According to the New York Times, a plan developed by the administration of former President Clinton "collapsed" in the face of Republican criticism (New York Times, 5/14).
News of the day
Diagnostics Waiting Times & Activity Data: Month Ending March 2009
This data shows the NHS" progress in tackling the waiting times for
Endocrinology

Numbers Of People With Dementia In Europe Higher Than Previously Reported

According to research reported at the Alzheimer"s Association 2009 International Conference on Alzheimer"s Disease (ICAD 2009) in Vienna, the number of people with Alzheimer"s disease and dementia in Europe may be higher than previously reported since both the number of new cases and the total number of people affected continue to rise among the very oldest segments of the population. The goal of the EuroCoDe (European Collaboration on Dementia) project, financed by the European Commission and coordinated by Alzheimer Europe, was to determine the prevalence of dementia in Europe based on up-to-date research findings. Dr Emma Reynish, a consultant geriatrician from the Victoria Hospital, Kirkcaldy, United Kingdom and her EuroCoDe colleagues conducted an extensive literature search using Cochrane review methodologies and compiled a database of all European epidemiological studies in the field up to the present date. 194 articles were identified by the review and 26 studies met inclusion criteria to participate with raw data in the collaborative analysis. According to Dr Emma Reynish, while dementia prevalence rates for all men and for women up to age 85 largely confirmed previous findings, age-specific prevalence rates were higher than previously documented in the female "oldest old" age groups, rising to over 50% in those over 95 years. "Our key findings confirmed that age remains as the single most important risk factor for dementia," Reynish said. "Nevertheless, due to the lack of data in the oldest old in previous prevalence studies, the prevalence of dementia of women over the age of 85 had been underreported." Jean Georges, Executive Director of Alzheimer Europe welcomed the findings: "These results are important for two reasons. Firstly, they confirm what we already knew about the prevalence of dementia in Europe for people up to the age of 85. At the same time, the reported prevalence in the oldest old shows that we have previously underreported the total number of people with dementia in Europe. In the European Union alone, we now estimate the total number of people with dementia to be 7.3 million, rather than 6.5 million. This poses important challenges for all European health care systems, since the oldest old is one of the fastest growing sectors of our European societies." Alzheimer Europe


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):